BN Business News
会社を追加 →
この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。

市場規制 · 1997/4/71 分で読めます

2943174 Canada Inc., Also d/b/a United Research Center, Inc.; Analysis To Aid Public Comment

ローカル自動翻訳 · 情報源の原言語

概要

In settlement of alleged violations of federal law prohibiting unfair or deceptive acts or practices and unfair methods of competition, this consent agreement, accepted subject to final Commission approval, would prohibit, among other things, the Quebec- based company and its president from making health benefits, performance, or efficacy claims regarding the ``Svelt-PATCH'' or any other drug or device unless, at the time the representation is made, the respondents possess and rely upon competent and reliable scientific evidence that substantiates the representation, and from misrepresenting the existence, contents, validity, results, conclusions, or interpretations of any test or study. In addition, the proposed consent agreement would require the respondents to pay $375,000 in consumer redress or disgorgement.

情報源の原言語: Federal Register — Federal Trade Commission原文の発表を開く →

関連インサイト

ビジネスインサイト →